iSBTc 24th Annual Meeting
Annual Meeting Main Page | Final Program | Program Purpose | Faculty | 
Presentation Slides & Schedule | Hot Topic Symposium | Friend of the President | Abstracts | Young Investigators | Award Winners | Photos
October 29 - 31, 2009
Gaylord National Hotel and Convention Center
Washington, D.C.
Program Schedule & Slides Download Final Program
To view slides from a presenter, click on the 
icon next to their name.
Wednesday, October 28 |
||
| 7:45 am - 7:00 pm | iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer For more information on the Workshop, click here. |
|
Thursday, October 29 |
||
| 7:50 am - 8:00 am | President's Welcome Bernard A. Fox, PhD - Earle A. Chiles Research Institute |
|
| 8:00 am - 8:45 am | Richard V. Smalley, MD Memorial Lectureship The Biology and Therapy of Brain Metastasis Isaiah J. Fidler, DVM, PhD - MD Anderson Cancer Center |
|
| 8:45 am - 11:30 am | Plenary Session: Human Immunology Co-Chairs: Jacques Banchereau, PhD - Baylor Institute for Immunology Research Adrian Hayday, PhD - King's College London |
|
| 8:45 am - 9:15 am | Dendritic Cells as Therapeutic Vaccines in Cancer Jacques Banchereau, PhD - Baylor Institute for Immunology Research |
|
| 9:15 am - 9:30 am | Identification of Colon Cancer Associated Antigens which would be Key Therapeutic Targets in the Prevention of Disease Relapse or Progression Elizabeth K. Broussard, MD - University of Washington Tumor Vaccine Group |
|
| 9:30 am - 10:00 am | Harnessing Invariant NKT Cells to Abolish the Suppressive Activity of Myeloid Derived Suppressor Cells and Restore Melanoma Specific Immune Response Vincenzo Cerundolo, MD, PhD - University of Oxford - Inst. of Molec. Medicine |
|
| 10:00 am - 10:15 am | Identification of a Novel CD8+CD57+ T Cell Subset in Human Melanoma Exhibiting an Incompletely Differentiated CTL Phenotype Richard Wu, BS - MD Anderson Cancer Center |
|
| 10:45 am - 11:00 am | A Data Analysis Method for Identifying Autoantibody Biomarkers in Cancer Patients Following Immunotherapy Janet Siebert, MD - CytoAnalytics |
|
| 11:00 am - 11:30 am | γ8 T Cells-Agents of Tissue and Tumour Immune Surveillance Adrian Hayday, PhD - King's College London |
|
| 11:30 am - 1:00 pm | Lunch with Poster Viewing and Exhibits | |
| 1:00 pm - 3:00 pm | Plenary Session: Enhancing Cancer Vaccines / Combinations Co-Chairs: Jeffrey Schlom, PhD - National Cancer Institute, NIH Laurence Zitvogel, MD, PhD - Institute Gustave Roussy |
|
| 1:00 pm - 1:25 pm | Enhancing Cancer Vaccines as Monotherapy and in Combination Therapies Jeffrey Schlom, PhD - National Cancer Institute, NIH |
|
| 1:25 pm - 1:50 pm | Defining the Role of TKIs in Reducing Immune Suppression While Improving T Cell Responsiveness and Efficacy of Immunotherapy for the Treatment of Tumors James H. Finke, PhD - Cleveland Clinic Foundation |
|
| 1:50 pm - 2:05 pm | Type-1 Dendritic Cell Vaccines in Combination With Poly-ICLC - Association Between Positive Tetramer Response and 6-Month Progression-Free Survival Hideho Okada, MD, PhD - University of Pittsburgh Cancer Institute |
|
| 2:05 pm - 2:30pm | IDO/IDO2 Inhibition: A New Strategy to Drive Immunotherapeutic Responses in Cancer by Reversing Tumoral Immune Tolerance George C. Prendergast, PhD - Lankenau Institute for Medical Research |
|
| 2:30 pm - 3:00 pm | How to Exploit the Immunogenicity of Chemotherapy or Radiotherapy Towards a Personalized Therapy of Cancer Laurence Zitvogel, MD, PhD - Institute Gustave Roussy |
|
| 3:00 pm - 3:15 pm | Break | |
| 3:15 pm - 4:45 pm | Concurrent Session I: Regulatory & Activated T Cell Subsets Co-Chairs: Charles G. Drake, MD, PhD - Johns Hopkins University Giorgio Trinchieri, MD - National Cancer Institute |
|
| 3:15 pm - 3:30 pm | CD81- A New Functional Marker for Tumor-induced Regulatory T Cells that Suppress Priming of Tumor-specific Effector T Cells in Reconstituted, Lymphopenic Hosts Christian H. Poehlein, MD - Earle A. Chiles Research Institute |
|
| 3:30 pm - 3:55 pm | Regulation of Tumor Immunity by NKT Cell Subsets Masaki Terabe, PhD - National Cancer Institute |
|
| 3:55 pm - 4:20 pm | IL-17 Secreting CD8 T Cells - Functional Plasticity and Potential Role in Tumor Immunity Charles G. Drake, MD, PhD - Johns Hopkins University |
|
| 4:20 pm - 4:45 pm | Interleukin-1 Role in Human TH17 Responses, Dendritic Cell Activation, and Epithelial Cell Transformation Giorgio Trinchieri, MD - National Cancer Institute |
|
| 3:15 pm - 4:45 pm | Concurrent Session II: Monoclonal Antibodies / Combinations Co-Chairs: Glenn Dranoff, MD - Dana-Farber Cancer Instiute Robert L. Ferris, MD, PhD - University of Pittsburgh Cancer Institute |
|
| 3:15 pm - 3:35 pm | FcγR Mediated Regulation of Adaptive Immunity: Implications for Antibody Therapies Madhav Dhodapkar, MD - Yale University |
|
| 3:35 pm - 3:50 pm | Synergy of Radiation and Immune Therapy in Tumor Eradication Maria Grazia Ruocco, PhD - NYU - School of Medicine, Skirball Institute |
|
| 3:50 pm - 4:10 pm | Enhancing Cancer Vaccines Glenn Dranoff, MD - Dana-Farber Cancer Institute |
|
| 4:10 pm - 4:25 pm | Antitumor Activity of Cytotoxic T-Lymphocyte Antigen-4 Blockade Alone or Combined with Paclitaxel, Etoposide, or Gemcitabine in Murine Models Maria Jure-Kunkel, PhD - Bristol-Myers Squibb Company |
|
| 4:25 pm - 4:45 pm | Immune Activation by Cetuximab Involves NK Cells, CTL and DC Against EGFR in Head and Neck Cancer Robert L. Ferris, MD, PhD, FACS - University of Pittsburgh Cancer Institute |
|
| 5:00 pm - 5:30 pm | iSBTc Membership Business Meeting | |
| 5:30 pm - 7:00 pm | Reception with Poster Viewing | |
Friday, October 30 |
||
| 8:00 am - 8:45 am | Keynote Address T Cell Recognition and the Coming Golden Age of Human Immunology and Immunotherapy Mark M. Davis, PhD - Howard Hughes Medical Institute / Stanford University School of Medicine |
|
| 8:45 am - 11:30 am | Plenary Session: Viral and Cellular Proteomic Targets Co-Chairs: Lieping Chen, MD, PhD - Johns Hopkins University School of Medicine Douglas R. Lowy, MD - National Cancer Institute, CCR |
|
| 8:45 am - 9:15 am | Current and Future Preventive HPV Vaccines Douglas R. Lowy, MD - National Cancer Institute, CCR |
|
| 9:15 am - 9:45 am | Therapeutic Strategies for Human Papillomavirus-Associated Cancers Karl Münger, PhD - Brigham & Women's Hospital, Harvard Medical School |
|
| 9:45 am - 10:15 am | Targets of Protective Tumor Immunity Glenn Dranoff, MD - Dana-Farber Cancer Institute |
|
| 11:00 am - 11:15 am | Definition of the Immunological Properties of Cancer Stem Cells Isolated from Human Glioblastoma Cristina Maccalli, PhD - San Raffaele Foundation Scientific Institute |
|
| 11:15 am - 11:30 am | Cell-Free EBV DNA is a Specific Biomarker for Tumour Burden in EBV-Associated Lymphomas Kimberley Jones - Queensland Institute of Medical Research |
|
| 11:30 am - 1:00 pm | Lunch with Poster Viewing and Exhibits | |
| 1:00 pm - 2:20 pm | iSBTc Presidential Session Chair: Bernard A. Fox, PhD - Earle A. Chiles Research Institute |
|
| 1:00 pm - 1:20 pm | T-Cell Delivery of Interleukin-12 to the Tumor Microenvironment Triggers Potent Endogenous Anti-Tumor Responses Sid Kerkar, MD - National Cancer Institute, Center for Cancer Research |
|
| 1:20 pm - 1:40 pm | Transduction of Tumor-Specific T Cells with the Gene Encoding CXCR2 Improves Migration to Tumor and In Vivo AntiTumor Immune Responses Weiyi Peng, MD, PhD - University of Texas MD Anderson Cancer Center |
|
| 1:40 pm - 2:00 pm | Eradication of Established CD19-Postive Leukemia Using a Single Injection of Chimeric Immunoreceptor Modified Lentiviral Transduced T Cells in a Xenograft Nog Mouse Model David M. Barrett, MD, PhD - Children's Hospital of Philadelphia |
|
| 2:00 pm - 2:20 pm | Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T Cell Depletion and Homeostatic Proliferation Presented by Thomas F. Gajeski, MD, PhD on behalf of Justin P. Kline, MD- University of Chicago |
|
| 2:20 pm - 2:45 pm | Break | |
| 2:45 pm - 4:15 pm | Concurrent Session I: Manipulation of the Tumor Microenvironment Co-Chairs: James P. Allison, PhD - Memorial Sloan-Kettering Cancer Center Dmitry I. Gabrilovich, MD, PhD - H. Lee Moffitt Cancer Center and Research Institute |
|
| 2:45 pm - 3:15 pm | Checkpoint Blockade in Tumor Immunotherapy: New Insights and Opportunities James P. Allison, PhD - Memorial Sloan-Kettering Cancer Center |
|
| 3:15 pm - 3:30 pm | Manipulation of the Tumor Microenvironment by CTLA-4 Blockade Padmanee Sharma, MD, PhD - MD Anderson Cancer Center |
|
| 3:30 pm - 4:00 pm | Myeloid-Derived Suppressor Cells and Tumor Microenvironment Dmitry I. Gabrilovich, MD, PhD - H. Lee Moffitt Cancer Center and Research Institute |
|
| 4:00 pm - 4:15 pm | Eosinophilic Granulocytes Modulate Tumor Microenvironment by Oxidizing Damage Associated Molecular Pattern Molecules Derived from Necrotic Tumor Cells Ramin Lotfi, MD - University of Ulm, Institute for Transfusion Medicine |
|
| 2:45 pm - 4:15 pm | Concurrent Session II: Targeted Therapeutics and Biological Therapy Co-Chairs: Richard Jove, PhD - City of Hope Cancer Institute David H. Munn, MD - Medical College of Georgia |
|
| 2:45 pm - 3:15 pm | Targeting Jak-Stat Signaling for Cancer Therapy Richard Jove, PhD - City of Hope Cancer Institute |
|
| 3:15 pm - 3:45 pm | Small-Molecule Inhibitors of the IDO Pathway as Immune Modulators David H. Munn, MD - Medical College of Georgia |
|
| 3:45 pm - 4:00 pm | Soluble, High Affinity T Cell Receptors as Cancer Therapeutics Bent Jakobsen - Immunocore Ltd. |
|
| 4:00 pm - 4:15 pm | Small Molecule Curcumin Analogs Induce Apoptosis in Human Melanoma Cells via STAT3 Inhibition but do not Alter the Cellular Response to Immunotherapeutic Cytokines Gregory B. Lesinski, PhD - The Ohio State University |
|
| 4:30 pm - 5:00 pm | Update: 2008 Workshop on Cancer & Inflammation: Promise for Biological Therapy Michael T. Lotze, MD - University of Pittsburgh Cancer Institute |
|
| 5:00 pm - 5:30 pm | Awards Presentation (View award recipients) | |
| 5:30 pm - 7:00 pm | Presidential Reception with Poster Viewing | |
Saturday, October 31 |
||
| 8:00 am - 10:15 am | Plenary Session: Adoptive Transfer Co-Chairs: Carl H. June, MD - University of Pennsylvania Steven A. Rosenberg, MD, PhD - National Cancer Institute |
|
| 8:00 am - 8:30 am | Cell Transfer Therapy for Patients with Metastatic Cancer Steven A. Rosenberg, MD, PhD- National Cancer Institute |
|
| 8:30 am - 9:00 am | What are the Functional and Phenotypic Qualities of Therapeutically Successful Anti-Tumor Cells? Nicholas P. Restifo, MD - National Cancer Institute |
|
| 9:00 am - 9:15 am | Programming Tumor-Reactive Effector Memory CD8+ T Cells In Vitro Obivates the Requirement for In Vivo Vaccination Christopher A. Klebanoff, MD - National Institutes of Health, Center for Cancer Research |
|
| 9:15 am - 9:45 am | Engineered T Cells for Cancer Therapy Carl H. June, MD - University of Pennsylvania |
|
| 9:45 am - 10:15 am | Adoptive Transfer of T Cells Genetically Modified Using the Sleeping Beauty System Laurence J.N. Cooper, MD - MD Anderson Cancer Center |
|
| 10:15 am - 10:20 am | Break | |
| 10:20 am - 12:00 pm | Hot Topic Symposium: Positive Immunotherapy Clinical Trial Outcomes Co-Chairs: Thomas F. Gajewski, MD, PhD - University of Chicago Drew M. Pardoll, MD, PhD - Johns Hopkins University School of Medicine |
|
| 10:20 am - 10:25 am | Welcome and Introductions Thomas F. Gajewski, MD, PhD - University of Chicago |
|
| 10:25 am - 10:45 am | Therapeutic Vaccines for Lymphoma: A Tale of Bench to Beside Translation Larry W. Kwak, MD, PhD - MD Anderson Cancer Center |
|
| 10:45 am - 11:05 am | A Phase III Multi-Institutional Randomized Study of Immunization with the gp 100:209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients with Metastatic Melanoma Doug J. Schwartzentruber, MD, FACS - Goshen Center for Cancer Care |
|
| 11:05 am - 11:25 am | Development History of Sipuleucel-T: Progress of an Active Immunotherapy for Prostate Cancer David L. Urdal, PhD - Dendreon Corporation |
|
| 11:25 am - 11:35 am | NY-ESO-1 Specific Responses in Patients with Advanced Prostate Cancer Treated wtih Ipilimumab Jianda Yuan, MD, PhD - Memorial Sloan-Kettering Cancer Center |
|
| 11:35 am - 11:45 am | Circulating Regulatory T Cell Function and Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Poxviral-based Vaccine Matteo Vergati, MD - National Cancer Institute, Center for Cancer Research |
|
| 11:45 am - 12:00 pm | Audience Discussion Moderator: Drew M. Pardoll, MD, PhD - Johns Hopkins School of Medicine |
|
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
